Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7126 to 7140 of 7675 results

  1. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    25 May 2005

  2. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)

    This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.

    Technology appraisal guidance
    Published
    24 August 2005

  3. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Technology appraisal guidance
    Published
    23 August 2000

  4. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Technology appraisal guidance
    Published
    25 May 2005

  5. Immunosuppressive therapy for renal transplantation in children and adolescents (TA99)

    This guidance has been updated and replaced by NICE technology appraisal guidance 482.

    Technology appraisal guidance
    Published
    26 April 2006

  6. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Technology appraisal guidance
    Published
    25 January 2006

  7. Dementia: support in health and social care (QS1)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    29 June 2010

  8. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Technology appraisal guidance
    Published
    27 January 2021

  9. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Technology appraisal guidance
    Published
    24 September 2003

  10. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

    Technology appraisal guidance
    Published
    23 July 2000

  11. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Technology appraisal guidance
    Published
    7 October 2020

  12. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Technology appraisal guidance
    Published
    30 June 2021

  13. Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA804.

    Technology appraisal guidance
    Published
    21 April 2021

  14. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

    Technology appraisal guidance
    Published
    28 April 2021

  15. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020